Oralair

Allergen Extract From Pollen Of Dactylis Glomerata, Anthoxanthum Odoratum, Lolium Perenne, Poa Prate, the active ingredient in Oralair, is a allergen immunotherapy presented as a sublingual tablet for sublingual use. It treats seasonal allergic rhinitis (hay fever) and allergic conjunctivitis caused by grass pollen in patients who experience these seasonal symptoms. GNH USA supplies Oralair as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Oralair is an allergen immunotherapy that targets grass‑pollen‑induced allergic disease. - Seasonal allergic rhinitis (hay fever): reduces nasal congestion, sneezing, itching and runny nose caused by grass pollen. - Allergic conjunctivitis due to grass pollen: alleviates eye itching, redness, tearing and swelling. - Grass‑pollen‑induced rhinoconjunctivitis: provides long‑term symptom control by inducing immune tolerance.

Oralair may cause local and systemic reactions after sublingual administration.

Common Side Effects: - Oral itching or mild throat irritation. - Mild ear or palate pruritus. - Transient gastrointestinal discomfort. - Local swelling of the mouth or tongue. - Mild headache. - Temporary increase in nasal congestion.

Serious or Rare Side Effects: - Anaphylaxis or severe systemic allergic reaction. - Angioedema involving the face, lips or airway. - Respiratory distress or bronchospasm. - Severe urticaria or widespread rash. - Cardiovascular collapse. - Persistent vomiting or severe gastrointestinal upset.

Before initiating Oralair, patients should be evaluated for suitability and instructed on proper administration. - Medical assessment: confirm diagnosis of grass‑pollen allergy and rule out uncontrolled asthma. - First dose supervision: administer the initial dose under medical observation. - Concomitant immunotherapy: avoid using other allergen extracts simultaneously. - Pregnancy and lactation: safety not established; discuss risks with a healthcare professional. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Oralair may interact with other medications that influence allergic responses or immune modulation.

Major Interactions (Avoid): - Concurrent use of other sublingual allergen extracts: risk of additive allergic reactions. - Beta‑blockers: may interfere with emergency treatment of anaphylaxis. - ACE inhibitors: may increase risk of angioedema.

Moderate Interactions (Monitor Closely): - Systemic corticosteroids: may reduce the effectiveness of immunotherapy. - Immunosuppressive agents: could diminish tolerance development. - Antihistamines: may mask early local reactions, requiring careful monitoring.